Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease - Archive ouverte HAL Access content directly
Journal Articles Annals of the Rheumatic Diseases Year : 2018

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease

(1, 2) , (3, 4) , , (5) , , (6) , (7) , (8) , (9) , (10, 11, 12) , (13) , , , , , ,
1
2
3
4
5
6
7
8
9
10
11
12
13
Cem Gabay
  • Function : Author
Department of Pathology and Immunology [Geneva, Switzerland]
Division of Rheumatology [Geneva, Switzerland]
Bruno Fautrel
Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie
Service de Rhumatologie [CHU Pitié Salpêtrière]
Jürgen Rech
  • Function : Author
François Spertini
  • Function : Author
Division of Immunology and Allergy [Lausanne, Suisse]
Eugen Feist
  • Function : Author
Ina Kötter
  • Function : Author
Department of Internal Medicine II, University of Tübingen
Eric Hachulla
  • Function : Author
Service de médecine interne [Lille]
Jacques Morel
Département de Rhumatologie[Montpellier]
Thierry Schaeverbeke
Rhumatologie Bordeaux
Mohamed Hamidou
  • Function : Author
Centre hospitalier universitaire de Nantes
Centre de Recherche en Transplantation et Immunologie
Institut de transplantation urologie-néphrologie
Thierry Martin
Laboratoire de Génie des Procédés et Matériaux - EA 4038
Bernhard Hellmich
  • Function : Author
Peter Lamprecht
  • Function : Author
Hendrik Schulze-Koops
  • Function : Author
Delphine Sophie Courvoisier
Andrew Sleight
  • Function : Author
Eduardo Jorge Schiffrin
  • Function : Author

Keywords

CRTI Team4

Domains

Life Sciences [q-bio] Immunology

Nicolas Degauque  : Connect in order to contact the contributor

https://www.hal.inserm.fr/hal-01881123

Submitted on : Tuesday, September 25, 2018-2:52:12 PM

Last modification on : Thursday, January 26, 2023-4:02:00 AM

Consult the full text

Dates and versions

hal-01881123 , version 1 (25-09-2018)

Identifiers

Cite

Cem Gabay, Bruno Fautrel, Jürgen Rech, François Spertini, Eugen Feist, et al.. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease. Annals of the Rheumatic Diseases, 2018, 13, pp.annrheumdis--2017--212608. ⟨10.1136/annrheumdis-2017-212608⟩. ⟨hal-01881123⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-NANTES LGPM CENTRALESUPELEC UNIV-PARIS-SACLAY CRTI SORBONNE-UNIVERSITE SU-MEDECINE GS-ENGINEERING NANTES-UNIVERSITE CR2TI
60 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More